Subscribe to RSS
DOI: 10.1160/TH06-05-0270
Leukemic lymphoblasts, a novel expression site of coagulation factor XIII subunit A
Financial support: This work was supported by grants from the University of Debrecen Medical and Health Science Center (Mec 13–2002), the Hungarian National Fund OTKA (T049392 and T043086) and the Hungarian Ministry of Health (ETT 355/2003).Publication History
Received
16 May 2006
Accepted after resubmission
07 July 2006
Publication Date:
28 November 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/200602/lookinside/thumbnails/10-1160-th06-05-0270-1.jpg)
Summary
Blood coagulation factor XIII (FXIII) is a protransglutaminase circulating asa tetramer formed by two types of subunits (A2B2). The intracellular dimeric form of FXIII (A2) is present in platelets, megakaryocytes, monocytes and macrophages and has been detected in mono-and megakaryocytic leukemias. The aim of our study was to investigate FXIII-A expression in newly diagnosed B cell acute lymphoblastic leukemia (ALL) samples. We examined 47 de novo ALL cases of B cell origin by triple color labeling with flow cytometry. FXIII-A was detected by a FITC conjugated monoclonal antibody combined with CD34 and CD45 staining. In selected cases FXIII-A was investigated on slides prepared from blasts and visualized with a fluorescent microscope. In addition, blasts were studied by Western blot analysis and FXIII-A was measured by a highly sensitive ELISA method. By flow cytometry 19 samples of the 47 cases were found to be FXIII-A positive. Antigen concentration was 3.11± 1.19 fg/blast, while normal lymphoid precursors and mature lymphocytes from B-CLL did not contain FXIII-A. In the lysate of lymphoblasts that were positive by flow cytometry, a single band (82 kDa) corresponding to FXIII-A was detected on Western blots. Confocal laser scanning microscopic examination revealed the presence of FXIII-A in the cytoplasm of these lymphoblasts. This novel expression site of FXIII-A in leukemic lymphoblasts can be utilized as a diagnostic tool and may also gain functional significance in B-lineage ALL.
* These authors contributed equally.
-
References
- 1 Muszbek L, Ádány R, Mikkola H. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 1996; 33: 357-421.
- 2 Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94: 271-305.
- 3 Muszbek L, Ádány R, Szegedi G. et al. Factor XIII of blood coagulation in human monocytes. Thromb Res 1985; 37: 401-10.
- 4 Henriksson P, Becker S, Lynch G. et al. Identification of intracellular factor XIII in human monocytes and macrophages. J Clin Invest 1985; 76: 528-34.
- 5 Ádány R, Belkin A, Vasilevskaya T. et al. Identification of blood coagulation factor XIII in human peritoneal macrophages. Eur J Cell Biol 1985; 38: 171-3.
- 6 Kiesselbach TH, Wagner RH. Demonstration of factor XIII in human megakaryocytes by a fluorescent antibody technique. Ann NY Acad Sci 1972; 202: 318-28.
- 7 Buluk K. An unknown function of blood platelets. Polski Tygod Lekar 1955; 10: 191-7.
- 8 Ádány R, Kiss A, Muszbek L. Factor XIII: a marker of mono-and megakaryocytopoiesis. Br J Haematol 1987; 67: 167-72.
- 9 Kappelmayer J, Bacskó G, Birinyi L. et al. Consecutive appearance of coagulation factor XIII subunit A in macrophages, megakaryocytes and liver cells during early phase of human development. Blood 1995; 86: 2191-7.
- 10 Kappelmayer J, Simon A, Katona E. et al. Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias. Thromb Haemost 2005; 94: 454-9.
- 11 Drexler HG, Thiel E, Ludwig WD. Review of the incidence and clinical relevance of myeloid antigenpositive acute lymphoblastic leukemia. Leukemia 1991; 05: 637-45.
- 12 Preti HA, Huh YO, O’Brien SM. et al. Myeloid markers in adult acute lymphoblastic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer 1995; 76: 1564-70.
- 13 Lauria F, Raspadori D, Martinelli G. et al. Increased expression of myeloid antigen markers in adult acute lymphoblastic leukemia patients: diagnostic and prognostic implications. Br J Haematol 1994; 87: 286-92.
- 14 Boldt DH, Kopecky KJ, Head D. et al. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group Experience. Leukemia 1994; 08: 2118-26.
- 15 Orfao A, Ciudad J, López-Berges MC. et al. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. Leuk Lymphoma 1994; 13 (Suppl. 01) 87-90.
- 16 Lucio P, Gaipa G, van Lochem EG. et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia: international standardization and clinical evaluation. Leukemia 2001; 15: 1185-92.
- 17 McKenna RW, Washington LT, Aquino DB. et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001; 98: 2498-507.
- 18 Katona E, Ajzner E, Tóth K. et al. Enzyme linked immunosorbent assay (ELISA) for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates. J Immunol Methods 2001; 258: 127-35.
- 19 Bene MC, Castoldi G, Knapp W. et al. „Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)”. Leukemia 1995; 09: 1783-6.
- 20 Buccheri V, Matutes E, Dyer MJS. et al. Lineage commitment in biphenotypic acute leukemia. Leukemia 1993; 07: 919-27.
- 21 Deptala A, Halicka HD, Salomon T. et al. Malignancy: A New Approach to the Analysis of Apoptosis in the Leukemic Subpopulation by Flow Cytometry Using a CD45 Gating Strategy. Hematology 1999; 04: 113-21.
- 22 Lacombe F, Durrieu F, Briais A. et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997; 11: 1878-86.
- 23 Kappelmayer J, Gratama JW, Karaszi E. et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interactions between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods 2000; 242: 53-65.
- 24 Invernizzi R, De Fazio P, Iannone AM. et al. Immunocytochemical detection of factor XIII A-subunit in acute leukemia. Leuk Res 1992; 16: 829-36.
- 25 Campana D, Coustand-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004; 112: 8-15.
- 26 Garcia JAVela, Monteserin MC, Delgado I. et al. Aberrant immunophenotypes detected by flow cytometry in acute lymphoblastic leukemia. Leuk Lymphoma 2000; 36: 275-84.
- 27 Ádány R, Bárdos H, Antal M. et al. Factor XIII of blood coagulation as a nuclear crosslinking enzyme. Thromb Haemost 2001; 85: 845-51.
- 28 Sárváry A, Szûcs S, Balogh I. et al. Possible role of factor XIII subunit A in Fcgamma and complement receptor-mediated phagocytosis. Cell Immunol 2004; 228: 81-90.
- 29 Törôcsik D, Bárdos H, Nagy L. et al. Identification of factor XIII-A as a marker of alternative macrophage activation. Cell Mol Life Sci 2005; 62: 2132-9.
- 30 Dardik R, Loscalzo J, Eskaraev R. et al. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005; 25: 526-32.